Taxonomy Icon
Ivy Brain Tumor Center Opens Novel Clinical Trial to Test Direct-to-Tumor Drug Delivery Method
  • July 18, 2023
In an effort to discover new treatments for brain tumors, such as glioblastoma, the Ivy Brain Tumor Center at Barrow Neurological Institute, announced the initiation of a ground-breaking Phase 0 clinical trial that tests a new experimental drug delivery method called superselective intra-arterial infusion, or SSIAI. This innovative approach can deliver highly-concentrated doses of experimental drugs directly to the tumor, potentially bypassing the blood-brain barrier and minimizing systemic side effects.
Taxonomy Icon
Ivy Brain Tumor Center Announces Interim Results of Two Clinical Trials Targeting High-Grade Glioma
  • June 2, 2023
The Ivy Center proudly announces our participation in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting for two Phase 0 clinical trials of infigratinib and niraparib in recurrent high-grade glioma and newly-diagnosed glioblastoma.
Taxonomy Icon
Ivy Brain Tumor Center Builds On Innovative Clinical Trial Program by Appointing New Chief Medical Officer
  • May 23, 2023
The Ivy Brain Tumor Center and Barrow Neurological Institute are pleased to announce the addition of Yoshie Umemura, MD, as the new Chief Medical Officer of the Ivy Brain Tumor Center and Division Chief of Neuro-Oncology and the William and Joan Shapiro Chair of Neuro-Oncology at Barrow Neurological Institute. 
Taxonomy Icon
Arizona Goes All In For Brain Tumor Awareness Month
  • May 1, 2023
The Ivy Brain Tumor Center is leading the way in brain cancer research and treatment. May is Brain Tumor Awareness Month and the Ivy Center has partnered with several major organizations across the state to bring much-needed attention to and support for Brain Tumor Awareness Month.
Taxonomy Icon
Ivy Center Investigator Awarded Grant for High-Risk, High-Impact Brain Cancer Research
  • November 10, 2022
Dr. An-Chi Tien, Pharmacodynamics Core Leader of the Ivy Center, is the recipient of the American Brain Tumor Association’s Discovery Grant, a one-year, $50,000 award, supporting faculty and scientists who propose high-risk, high-impact research with the potential to change current diagnostic or treatment models for brain tumor care. 
Taxonomy Icon
Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress
  • September 10, 2022
Presented today at the ESMO Congress, Dr. Nader Sanai announced initial results in our Phase 0 clinical trial evaluating pamiparib in patients with #glioblastoma (NCT04614909). The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients.
Taxonomy Icon
Ivy Brain Tumor Center Implements New Liquid Biopsy Program to Provide Glioblastoma Patients More Personalized Care
  • September 7, 2022
The Ivy Brain Tumor Center announced its initiation of a ‘Liquid Biopsy’ program to obtain real-time insights into how a patient’s brain tumor is responding to experimental treatment. 
Taxonomy Icon
Ivy Brain Tumor Center Announces Launch of Spanish-Language Website
  • June 15, 2022
Ivy Brain Tumor Center has launched a new Spanish-language website, providing information and resources about brain cancer for Spanish-speaking communities. Check it out now.
Taxonomy Icon
Ivy Brain Tumor Center Opens New Clinical Trial for Patients with Recurrent Grade IV Gliomas
  • March 16, 2022
Ivy Brain Tumor Center is conducting a new clinical trial for patients with recurrent Grade IV gliomas. Learn about the study and how it could improve brain cancer treatments.
Taxonomy Icon
Ivy Brain Tumor Center’s Core Laboratories Awarded Accreditation by the College of American Pathologists
  • December 21, 2021
The Ivy Brain Tumor Center, the largest early-phase drug development program for brain cancer in the world, announced that its Pharmacodynamics (PD) Core and Pharmacokinetics (PK) Core laboratories passed their inspection and maintained accreditation by the Accreditation Committee of the College of American Pathologists (CAP).